ErbB2/Her2 anticorps (C-Term)

N° du produit ABIN499802

Détail du produit anti-ErbB2/Her2 anticorps

Antigène: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Épitope: C-Term

Reactivité: Humain, Souris, Rat

Hôte: Poulet

Clonalité: Polyclonal

Conjugué: Cet anticorp ErbB2/Her2 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Specificité: This antibody reacts to erbB-2.

Purification: Affinity chromatography purified via peptide column

Immunogène: erbB-2 antibody was raised against a 19 amino acid peptide near the carboxy terminus of human erbB-2.

Isotype: IgG

Information d'application

Indications d'application: ELISA. Western Blot: 1 - 2 μg/mL. Immunohistochemistry.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Buffer: PBS containing 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C.

Détails sur ErbB2/Her2

Antigène: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Autre désignation: CD340 / ERBB2 / HER2 (ErbB2/Her2 Produits)

Synonymes: anticorps CD340, anticorps HER-2, anticorps HER-2/neu, anticorps HER2, anticorps MLN 19, anticorps NEU, anticorps NGL, anticorps TKR1, anticorps Erbb-2, anticorps Neu, anticorps c-erbB2, anticorps c-neu, anticorps mKIAA3023, anticorps wu:fv70f10, anticorps zgc:63601, anticorps erb2, anticorps erb-b2 receptor tyrosine kinase 2, anticorps ERBB2, anticorps Erbb2, anticorps erbb2

Sujet: The ErbB family consists of four closely related tyrosine kinase receptors that act as potent mediators of normal cell growth and development. Aberrant expression or function of one or more of these receptors can play a major role in the development and evolution of cancer. ErbB-2, also known as HER2, has been implicated in the evolution of both breast and gastric cancers, and is evident in other cancer types such as ovarian and salivary gland tumors. ErbB-2 possesses an active tyrosine kinase domain, but no direct ligand has been identified yet. ErbB-2 is the preferred binding partner to the other members of the ErbB family and is thought to act primarily through the Ras-MAPK, PI3k-PKB/Akt, and PLC-PKC signaling pathways. Numerous anti-cancer strategies have been employed against erbB-2, such as antibody-based therapies to prevent ligand binding or receptor activation through dimerization, antibody-dependent cell mediated cytotoxicity, in addition to direct kinase inhibition to prevent molecular activation/downstream signaling.Synonyms: HER-2, MNL19, NEU, NEU proto-oncogene, NGL, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, c-erbB-2, p185erbB2

ID gène: 2064

NCBI Accession: NP_004439

UniProt: P04626

Pathways: Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development